|
[Related PubMed/MEDLINE]
Total Number of Papers: 58
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
The neuroprotective effect of pterostilbene on oxaliplatin-induced peripheral neuropathy via its anti-inflammatory, anti-oxidative and anti-apoptotic effects: Comparative study with celecoxib. |
MDA, TAC |
| 2 |
2022 |
A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice. |
ROS, SOD |
| 3 |
2022 |
Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. |
HMGB1 |
| 4 |
2022 |
Diosgenin relieves oxaliplatin-induced pain by affecting TLR4/NF-κB inflammatory signaling and the gut microbiota. |
--- |
| 5 |
2022 |
Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial. |
CTCAE, NCS |
| 6 |
2022 |
Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients. |
ADI, AI, BJOEI, CKSI, EEI, HCSI, KAI, KLEI, LI, NMA, RCTs, SFI, SIFZI, SMI, TCMIs, XAPI |
| 7 |
2022 |
NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. |
EPA, NET, NLRP3 |
| 8 |
2022 |
New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy. |
CTCAE, PTT, QST |
| 9 |
2022 |
Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database. |
FAERS, PPI |
| 10 |
2022 |
Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy. |
--- |
| 11 |
2022 |
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. |
BMI, CTCAE |
| 12 |
2022 |
Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis. |
BMI, CI, OR |
| 13 |
2022 |
Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. |
GRADE |
| 14 |
2022 |
Protective Mechanism of Electroacupuncture on Peripheral Neurotoxicity Induced by Oxaliplatin in Rats. |
DRG, EA, HO-1, Nrf2, TRP |
| 15 |
2022 |
Syringaresinol Alleviates Oxaliplatin-Induced Neuropathic Pain Symptoms by Inhibiting the Inflammatory Responses of Spinal Microglia. |
iNOS, p-ERK, p-NF-kappaB |
| 16 |
2022 |
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. |
--- |
| 17 |
2022 |
Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months. |
--- |
| 18 |
2022 |
The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. |
CRC, DEGs, HDAC, HDACi |
| 19 |
2022 |
[Preparation of microemulsion gel loading enriched ingredients of Epimedii Folium and its pharmacodynamics evaluation]. |
CIPN |
| 20 |
2021 |
Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial. |
PA, QoL |
| 21 |
2021 |
Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial. |
GI, PN, QoL |
| 22 |
2021 |
Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial. |
DFS, MCIPN, OS, PFS, VAS |
| 23 |
2021 |
PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-kappaB/Nrf-2 Axis. |
DRG, PEA-OXA, PEAum |
| 24 |
2021 |
Platinum accumulation in oxaliplatin-induced peripheral neuropathy. |
CTR1, MATE1 |
| 25 |
2021 |
Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. |
DSD, HGWD, YWF |
| 26 |
2021 |
Probing the peripheral immune response in mouse models of oxaliplatin-induced peripheral neuropathy highlights their limited translatability. |
CIPN |
| 27 |
2021 |
Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. |
CRC, CTSS, IL-10, IRF1 |
| 28 |
2020 |
A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study. |
--- |
| 29 |
2020 |
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. |
NCI-CTCAE |
| 30 |
2020 |
Based on Systematic Pharmacology: Molecular Mechanism of Siwei Jianbu Decoction in Preventing Oxaliplatin-Induced Peripheral Neuropathy. |
CIPN, IENF |
| 31 |
2020 |
Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. |
FN, Nrf2 |
| 32 |
2020 |
Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. |
--- |
| 33 |
2020 |
Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. |
GGT, Hgb |
| 34 |
2020 |
Qualitative Evaluation of the Influence of Acute Oxaliplatin-Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life. |
QoL |
| 35 |
2020 |
Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. |
NCI-CTC, OCT, sGFAP, sNfL |
| 36 |
2020 |
Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial. |
TCM |
| 37 |
2020 |
Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). |
mCRC |
| 38 |
2020 |
Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study. |
CINQ, PQAS |
| 39 |
2019 |
Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study. |
ADL |
| 40 |
2019 |
Differential protein expression profiling by iTRAQ-2D-LC-MS/MS of rats treated with oxaliplatin. |
--- |
| 41 |
2019 |
Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. |
--- |
| 42 |
2019 |
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. |
CRC, DFS |
| 43 |
2018 |
A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy. |
NCS |
| 44 |
2018 |
Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy. |
ESC |
| 45 |
2018 |
Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. |
NF-E2 |
| 46 |
2018 |
Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy. |
AMPK, CIPN, DRG, RA |
| 47 |
2017 |
Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy. |
DRG |
| 48 |
2017 |
Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. |
DRG |
| 49 |
2017 |
Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. |
TNSc |
| 50 |
2016 |
An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi. |
CPT, GJG |
| 51 |
2016 |
Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study. |
CINQ, LA, OSNS, PQAS |
| 52 |
2016 |
Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. |
CRC, QoL |
| 53 |
2015 |
Calcium-related neurotoxicity of oxaliplatin: understanding the mechanisms to drive therapy. |
--- |
| 54 |
2015 |
Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. |
HRQoL, PRD |
| 55 |
2015 |
Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study. |
ICC, OANQ |
| 56 |
2014 |
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. |
NCI-CTC |
| 57 |
2014 |
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. |
CR, CRC |
| 58 |
2011 |
Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. |
VAS |
|
A Search Service for Abbreviation / Long Form
